Baidu
map

Chest:接受CPAP的高心血管风险OSA患者多模式远程监测效果

2018-11-23 xing.T MedSci原创

由此可见,在具有高心血管风险的OSA患者中,多模式远程监护在改善家庭血压方面并不优于通常的CPAP护理。然而,远程监护改善了依从性和以患者为中心的结果。

对高血管风险的阻塞性睡眠呼吸暂停(OSA)患者的管理必须不仅要改善对持续气道正压通气(CPAP)的依从性,还应旨在降低血压(BP)和增加身体活动。近日,呼吸领域权威杂志chest上发表了一篇研究文章,该研究旨在评估使用远程患者监护在降低高血管风险的OSA患者血压方面综合干预的有效性。

在一项多中心、开放、随机试验中,OSA患者在CPAP开始时被随机分配到常规护理或多模式远程监护6个月组。远程监护使用电子设备收集有关血压、症状、CPAP副作用和身体活动等信息。研究人员使用家庭自测血压(HBP)连续3天评估主要有效性结果。次要结果包括CPAP依从性、症状和身体活动。

306名参与者年龄为61.3岁[54.1-66.1];主要为男性,有226人(74%),体重指数为32.0 [28.7-35.6]kg/m2,呼吸暂停低通气指数为46 [35-61]次事件/小时,149名参与者接受常规治疗,157人接受远程监护。经过6个月的CPAP,HBP在各组之间没有显著差异。在次级分析中,每天的步数没有显著差异,但CPAP依从性显著增加,并且有利于多模式远程监护参与者白天嗜睡和生活质量的改善。

由此可见,在具有高心血管风险的OSA患者中,多模式远程监护在改善家庭血压方面并不优于通常的CPAP护理。然而,远程监护改善了依从性和以患者为中心的结果。

原始出处:

Jean-Louis Pépin,et al.Multimodal remote monitoring of high cardiovascular risk OSA patients initiating CPAP: a randomized trial.chest.2018.https://doi.org/10.1016/j.chest.2018.11.007

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2019-03-16 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-25 bioon3
  8. [GetPortalCommentsPageByObjectIdResponse(id=1929531, encodeId=69ee19295316d, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Mar 16 19:02:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051289, encodeId=2e33205128969, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 03 08:02:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663107, encodeId=1073166310ec0, content=<a href='/topic/show?id=d0d7102384ee' target=_blank style='color:#2F92EE;'>#高心血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102384, encryptionId=d0d7102384ee, topicName=高心血管风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bea25523459, createdName=ms1065684921169360, createdTime=Sat Jan 19 09:02:00 CST 2019, time=2019-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030166, encodeId=0bce203016601, content=<a href='/topic/show?id=d88913e2636' target=_blank style='color:#2F92EE;'>#PAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13726, encryptionId=d88913e2636, topicName=PAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Mon Apr 01 03:02:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082481, encodeId=be77208248140, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Mar 29 09:02:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331370, encodeId=c10713313e02d, content=<a href='/topic/show?id=1b32515586' target=_blank style='color:#2F92EE;'>#CPAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5155, encryptionId=1b32515586, topicName=CPAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349779, encodeId=cbf61349e7978, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Nov 25 13:02:00 CST 2018, time=2018-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046680, encodeId=319b10466809f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Nov 24 01:02:00 CST 2018, time=2018-11-24, status=1, ipAttribution=)]
    2018-11-24 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

JAHA:睡眠呼吸暂停、心衰风险以及CPAP治疗的潜在益处

由此可见,在这项全国范围的队列研究中,没有接受CPAP治疗的SA与所有年龄段患者HF发生风险增加有关。使用CPAP治疗与60岁以上患者较低的HF风险有关,这表明CPAP治疗对老年人有保护作用。

Eur Respir J:CPAP治疗对阻塞性睡眠呼吸暂停合并冠状动脉疾病患者结局的影响!

由此可见,采用CPAP治疗的OSA合并CAD患者与无OSA的患者相比MACCEs的风险并未增加。

2018 昆士兰临床指南:新生儿呼吸窘迫包括CPAP

2018年7月,昆士兰卫生组织(QLD)更新发布了新生儿呼吸窘迫包括CPAP的管理指南,该指南是对2014年版指南的修正,主要内容包括氧饱和度目标范围更新,并添加相关术语,修正一些小的错误,增补第4部分安全和质量标准更新。

Chest:运动训练和CPAP对心力衰竭和OSA患者的影响

由此可见,在HF和OSA患者中,该研究的初步结果显示单独的运动可以改善OSA,提高生活质量,但CPAP不能。在HF患者OSA的治疗中,该研究是唯一的一项显示任何治疗(运动)可改善所有研究参数的随机试验。该研究的结果突出了运动的重要治疗益处,特别是对于CPAP依从性较低的个体。

Eur Respir J:持续气道正压对2型糖尿病合并阻塞性睡眠呼吸暂停患者视力的影响

与12个月以上的常规护理相比,采用CPAP治疗OSA并未改善2型糖尿病合并DMO患者的视力。

Eur Respir J:持续气道正压通气对左室舒张功能的影响!

由此可见,在重度OSA患者中,CPAP治疗3个月可以显著改善左室舒张功能,相比于假治疗,并且可以同时改善动脉硬化和心室血管耦合。

Baidu
map
Baidu
map
Baidu
map